The FDA has granted clearance to an investigational new drug application for CLD-201 for solid tumor treatment, based on preclinical findings.

The 7MM soft tissue sarcoma (STS) market is estimated to reach USD 6,465.7 million by 2030 from USD 2,943.3 million in 2019 at a CAGR of 7.4%.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering targeted antitumor virotherapies, announced today that the U.S. Food and Drug ...

Eldiara was diagnosed with stage 3 synovial sarcoma, a rare type of soft tissue cancer, when she was just 19 years old – and ...

Eldiara was diagnosed with stage 3 synovial sarcoma, a rare type of soft tissue cancer, when she was just 19 years old – and ...

Introduction The global Soft Tissue Sarcoma (STS) market has demonstrated significant growth potential, with projections estimating the market to grow at a Compound Annual Growth Rate (CAGR) of 7.4% ...